BDTX Stock Summary and Trading Ideas (Black Diamond Therapeutics | NASDAQ:BDTX)

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

What symbol and exchange does Black Diamond Therapeutics shares trade?

Black Diamond Therapeutics trades on the NASDAQ stock market under the symbol BDTX.

What is Black Diamond Therapeutics stock price doing today?

As of August 19, 2026, BDTX stock price climbed to $2.19 with 814,294 million shares trading.

What is Black Diamond Therapeutics's Beta?

BDTX has a beta of 2.46, meaning it tends to be more sensitive to market movements. BDTX has a correlation of 0.17 to the broad based SPY ETF.

How much is Black Diamond Therapeutics worth?

BDTX has a market cap of $125.46 million. This is considered a Micro Cap stock.

How much money does Black Diamond Therapeutics make?

Last quarter Black Diamond Therapeutics reported $0 in Revenue and -$.17 earnings per share. This fell short of revenue expectation by $-30 million and exceeded earnings estimates by $.03.

What is the highest and lowest price Black Diamond Therapeutics traded in the last 3 year period?

In the last 3 years, BDTX traded as high as $7.66 and as low as $1.20.

What are the top ETFs holding Black Diamond Therapeutics?

The top ETF exchange traded funds that BDTX belongs to (by Net Assets): VTI, IWM, FESM, SMLF, IWN.

Is Black Diamond Therapeutics (BDTX) a good investment?

BDTX has underperformed the market in the last year with a return of -20.4%, while the SPY ETF gained +20.7%. In the last 3 month period, BDTX fell short of the market, returning -15.1%, while SPY returned +4.4%. However, in the most recent 2 weeks BDTX has outperformed the stock market by returning +23.0%, while SPY returned -0.3%.

What are the support and resistance levels for Black Diamond Therapeutics (BDTX)?

BDTX support price is $1.99 and resistance is $2.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BDTX shares will trade within this expected range on the day.